Medindia

X

Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008

Tuesday, November 18, 2008 General News J E 4
Advertisement
MALVERN, Pa., Nov. 18 Arlington Medical Resources (AMR), aprovider of premier market intelligence for the pharmaceutical and diagnosticimaging industries, finds that over $10 million of CSL Behring's Privigen wassold in the U.S. during the third quarter of 2008. Privigen is the newestbrand of intravenous immune globulin (IVIG) and was launched in the firstquarter of 2008. IVIG is a product created from the blood plasma of thousandsof donors and is used to treat immune deficiencies, inflammatory andautoimmune diseases, acute infections and various other diseases.

The newly released edition of the IVIG Market Guide (U.S.) also finds thatBaxter sold more grams of IVIG to hospitals than any other company in the U.S.during the third quarter of 2008. Baxter is currently the leader in hospitalsales of IVIG.

"Based on recent news, if CSL Behring acquires Talecris, CSL Behring'smarket share of IVIG will increase significantly and could potentially surpassBaxter as the leader in hospital sales of IVIG," added Matthew W. Mahr,Pharm.D., M.B.A., analyst at AMR.

Why Pharmaceutical Companies Need this Information

The IVIG Market Guide (U.S.) enables pharmaceutical companies to monitorhospital utilization rates of intravenous immune globulin products. The datacaptured in this audit reveals usage by indication, dosing, ordering physicianspecialty and patient demographics for recipients of this group of products.

About The IVIG Market Guide (U.S.)

The IVIG Market Guide (U.S.) is the industry's most comprehensive marketresearch study of IVIG. This product has two separate components including TheIVIG Hospital Patient Profile Reports and The IVIG Hospital Purchasing Audit.The purchasing audit provides IVIG product market shares (in grams anddollars) and is produced twice a year. The patient profile report identifiesrelative usage patterns by indication, patient demographics, prescribingphysician, dosing and insurance coverage and is produced once a year.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of thepharmaceutical and diagnostic imaging industries. Research includes clinicalinpatient databases that directly link anti-infective drug withindication/procedure, formulary and stocking status tracking studies, drugpurchasing audits and diagnostic imaging procedure volume/contrast media usageaudits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. atwww.DecisionResourcesInc.com.

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.com

SOURCE Arlington Medical Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Indevus Pharmaceuticals to Announce Fiscal 2008 Fi...
S
Mylan Receives Final FDA Approval for the Generic ...